Trilio Announces Technical Preview of ‘Continuous Restore,’ Delivering Cloud-Native Application Portability and Recoverability in Seconds Across Disparate Infrastructure
17.5.2022 14:05:00 EEST | Business Wire | Press release
KUBECON + CLOUDNATIVECON EUROPE— Trilio, a leading provider of cloud-native data protection, today announced a technical preview of a new “Continuous Restore” capability that is being showcased to the cloud-native community at the KubeCon + CloudNativeCon Europe conference. Continuous Restore offers faster levels of replication, restoration and migration of data and metadata from any storage or cloud platform to another, dramatically improving recovery times for cloud-native applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220517005514/en/
New capability unlocks data gravity and frees data-driven organizations to quickly replicate production-grade Cloud-Native applications to any cloud in seconds. (Graphic: Business Wire)
Entirely storage-, cloud- and distribution-agnostic, Trilio’s “Continuous Restore” capability will enable users to continuously stage data at multiple and heterogeneous clouds. This means that applications—regardless of where they reside—will be able to tap into that data and be brought online in seconds, achieving exceptional levels of Recovery Time Objectives (RTO). The capability will be introduced as part of the TrilioVault for Kubernetes cloud-native data protection and management platform.
“Distributed environments consisting of core, edge and cloud resources are becoming the predominant architecture for enterprises today,” said Murali Balcha, Founder and CTO of Trilio. “Companies frequently need to move stateful applications and their data volumes among these diverse environments to achieve cost-efficiency, performance, security and disaster recovery imperatives. Unfortunately, no easy-to-use, affordable solution for continuous data volume replication across heterogeneous infrastructure environments exists today.”
“Trilio’s Continuous Restore capability enables migration and replication of stateful applications in seconds or minutes so that all companies can protect and use their data anywhere—regardless of what the application runs on or where the data is stored,” continued Balcha. “This provides organizations the ability to meet leading levels of application uptime, achieve Service Level Agreements (SLAs) expected of production-grade applications—all at an affordable cost. Continuous Restore is a game-changer that will make today’s modern businesses even more competitive and resilient.”
***To see a Demo of Continuous Restore, visit Trilio at Booth P11 at KubeCon + CloudNativeCon Europe or schedule a meeting with our K8s Experts***
Use cases for the Continuous Restore capability include:
1. Disaster Recovery: Users will be able to achieve availability objectives and recover from outages or failures in a matter of seconds or minutes rather than days or weeks. Using Continuous Restore, Recovery Time Objectives (RTO) will improve by over 80% versus traditional methods.
2. Application Migrations: Continuous Restore allows IT teams to optimize performance and achieve better Total Cost of Ownership (TCO) by choosing the infrastructure best suited to current needs. The Continuous Restore capability will also enable organizations to unify their infrastructure, especially those that have grown quickly and adopted a variety of compute platforms and storage solutions to meet unique needs. Continuous Restore will make possible tremendously fast application mobility across infrastructure silos, making them silos no more.
3. Testing/Development: Developers can increase the velocity of CI/CD pipelines by staging data for multiple test/dev environments. These test/dev environments can be spun up in seconds with continuously replicated production data and accelerating the push of validated changes into production. In fact, DevOps teams can use this capability to test their “restore” protocols to ensure that restore will work when needed.
4. Data Curation from Edge Clouds: As distributed environments proliferate in the future, massive amounts of data will be collected at “the edge,” and this information from diverse architectures will need to be rapidly replicated and moved throughout distributed systems where it can be assimilated and centrally analyzed by any number of different applications.
Attend Trilio’s Session: “ Cloud-Native App Recoverability & Portability in a Matter of Seconds thru the Unification of Information Silos'' on Thursday May 19 3pm CET at the Microsoft Azure Booth P12. Join Ben Morrison, solution architect at Trilio, for his presentation and demo showcasing Trilio's capability for migrating a stateful application from on-prem Red Hat OpenShift to Azure AKS in a matter of seconds — highlighting the flexibility and speed enabled by the TrilioVault for Kubernetes platform.
Continuous Restore is a capability within TrilioVault for Kubernetes and will be made generally available as part of a product release in Q3’22. For those that want to preview or test the capability, please contact Trilio.
About Trilio
Trilio is a leader in cloud-native data protection for Kubernetes, OpenStack and Red Hat Virtualization environments. Our TrilioVault technology is trusted by cloud infrastructure operators and developers for backup and recovery, migration and application mobility. Customers in telecom, defense, automotive and financial services leverage TrilioVault to recover from disasters, migrate workloads, move workloads to new infrastructure and migrate to new software distributions. Trilio.io, Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005514/en/
Contact information
Media:
Robert Cathey
Cathey.co for Trilio
robert@cathey.com
865-386-6118
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom